Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
Gilead participates in a conference call with Leerink
Leerink hosts a conference call with management on May 25 at 11:30 am.
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
Gilead Q1 results poised to beat expectations, says Wells Fargo
After analyzing prescription data for January and February, Wells Fargo says that prescriptions of Gilead's HIV and HCV drugs were tracking ahead of expectations. The firm says the company's Q1 results appear on track to beat expectations.
Piper Jaffray 'encouraged' by Gilead ACC inhibitor data in NASH
Piper Jaffray analyst Joshua Schimmer said Gilead's GS-0976 program in the treatment of NASH are the company's "most interesting" and the just announced data for the ACC inhibitor in a 10 patient study are very encouraging. The analyst, who continues to believe that reducing lipids is a key component for treating NASH, added that long term safety for inhibition of ACC will be necessary before he can have confidence in the program's potential. He keeps an Overweight rating on Gilead shares.
Jefferies uncovers 'unnoticed' positive NASH data coming from Gilead
Jefferies analyst Brian Abrahams said his review of titles for the upcoming EASL meeting of the International Liver Congress appears to indicate that Gilead's ACC inhibitor GS-0976, which he calls "one of [the company's] least-talked-about assets in NASH," demonstrated significant positive effects in an as-yet-unreported phase 2 study. The analyst, who calls the presentation "unnoticed" and "not broadly discussed," believes the study may meaningfully de-risk a second NASH asset and could set the stage for increasing enthusiasm around Gilead's NASH program over the next 12 months. Abrahams keeps a Buy rating on Gilead shares. The ILC meeting is being held from April 19 to 23 in Amsterdam.
TODAY'S FREE FLY STORIES